The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimulation test at Week 24 was 94%, and the results were statistically significant (P-value=0.0005), which exceeded the pre-specified success criterion. Leuprolide...
Hence then, the article about foresee pharmaceuticals announces the casppian phase 3 study meets primary efficacy endpoint demonstrating robust lh suppression with 6 month dosing interval of leuprolide mesylate was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide mesylate )
Also on site :
- Viola Davis, 61, Opens Up About ‘Extremely Painful’ Health Condition for the First Time: ‘It Terrified Me’ (Exclusive)
- Rosalía Shuts Down Kenan Thompson’s Idea for a Pop-Classical Album in Hilarious ‘SNL’ Promo: ‘That’s LUX’
- In 1924, Caesar Cardini ran out of kitchen supplies in a Fourth of July rush at his Tijuana restaurant; he tossed romaine with what was left, and the salad carries his name